Study Findings on Melanoma Are Outlined in Reports from University of Turin (Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma).

Předmět:	NUCLEAR factor E2 related factor MELANOMA LIFE sciences IPILIMUMAB REPORTERS & reporting PROTEIN stability
Zdroj:	Drug Week; 7/14/2023, p1150-1150, 1p
Abstrakt:	Taking advantage of established in vitro melanoma models resistant to BRAFi, MEKi, or dual resistance to BRAFi/MEKi, we demonstrated that Nrf2 was upregulated in melanoma cells resistant to targeted therapy at the post-translational level and that the deubiquitinase DUB3 participated in the control of the Nrf2 protein stability." Keywords: Cancer; Drugs and Therapies; Health and Medicine; Melanoma; Oncology EN Cancer Drugs and Therapies Health and Medicine Melanoma Oncology 1150 1150 1 07/10/23 20230714 NES 230714 2023 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on melanoma have been published. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu